...Mehri Haeili; Ali Abdollahi; Amin Ahmadi; Amin Khoshbayan Introduction: Tigecycline (TGC) is one of the last-resort therapeutic agents for treating infections caused by extensively drug resistant Acinetobacter baumannii isolates. Although resistance to TGC is not common, non-susceptible...

...Huale Chen; Jianming Cao; Cui Zhou; Haiyang Liu; Xiaoxiao Zhang; Tieli Zhou Background: Tigecycline, one of the few therapeutic options against multidrug-resistant Acinetobacter baumannii, reaches subinhibitory serum concentrations only with cautious clinical dosing and pharmacokinetics...

...Arne C. Rodloff; Michael J. Dowzicky Background: European centers (n = 226) involved in the Tigecycline Evaluation and Surveillance Trial (TEST, 2004-2014) submitted data and bacterial isolates. Methods: Minimal inhibitory concentrations and susceptibility were determined using Clinical...

...Li Xu; Ya-Li Wang; Shuai Du; Lin Chen; Li-Hui Long; Yan Wu Background: Tigecycline is an antibiotic agent with a broad spectrum, which has an antibacterial effect against many multidrug-resistant organisms. However, its clinical efficacy in the treatment of hospital-acquired pneumonia (HAP...

...Sezen Özkök; Turhan Togan; Ayşegül Yesilkaya; Funda Timurkaynak; Özlem Kurt Azap; Hande Arslan Background and Aim: Tigecycline is a semi-synthetic tetracycline with activity against most multidrug-resistant (MDR) bacteria. Methods: We studied in vitro activity of tigecycline by agar dilution (AD...

... was to investigate the additional effect of sulbactam on monotherapy with colistin, tigecycline and imipenem in experimental sepsis with carbapenem-resistant A. baumannii in mice. Methods: Sepsis was developed in 8- to 10-week-old BALB/c mice by an intraperitoneal injection of A. baumannii. Antibiotic was given...

...Klaus-Friedrich Bodmann; Wolfgang R. Heizmann; Christof von Eiff; Christian Petrik; Peter-Andreas Löschmann; Christian Eckmann This large prospective non-interventional study investigated the effects of tigecycline either as single agent or in combination with other antimicrobial agents in 1,025...

..., in 2008, to 5.2 and 2.4%, respectively, in 2009. Two E. coli and 3 Klebsiella pneumoniae ESBL producers were non-susceptible to ertapenem, most likely due to loss of porins. Antimicrobial susceptibility testing of selected, molecularly characterized ESBL producers revealed susceptibility to tigecycline...

...Christian Eckmann; Wolfgang R. Heizmann; Eva Leitner; Christof von Eiff; Klaus-Friedrich Bodmann Background: Only few data are available on the efficacy of tigecycline in critically ill patients. Methods: This prospective, multicenter, non-interventional study investigated the efficacy and safety...

...Berna Özbek; Aylin Şentürk Background: Colistin sulfate and levofloxacin, alone and in combination with tigecycline, were investigated for their in vitro activities and postantibiotic effects (PAEs) on6 meropenem-resistant Acinetobacter baumannii . Methods: The in vitro activities of colistin...

...Sadia Shakoor; Erum Khan; Afia Zafar; Rumina Hasan Background: The Aga Khan University Hospital is a tertiary care centre in Karachi, Pakistan, where tigecycline has not been used previously. We report findings of a pre-use in vitro study to evaluate sensitivity of nosocomial Acinetobacter spp...

...Harald Seifert; Michael J. Dowzicky Background: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) global surveillance program has been designed to assess the in vitro activity of the broad-spectrum antimicrobial agent tigecycline plus several comparative agents. Methods: In vitro...

...Nevriye Gonullu; Fadimana Catal; Omer Kucukbasmaci; Sinem Ozdemir; Muzeyyen Mamal Torun; Rahmiye Berkiten Background: We compared the in vitro activities of tigecycline with those of other agents against 97 Streptococcus pneumoniae, 140 Haemophilus influenzae and54 Moraxella catarrhalis strains...

...Liliana Fernández Canigia; Sara Kaufman; Liliana Lanata; Carlos Vay; Marta Giovanakis; Carlos Bantar Background: Tigecycline is a new antibiotic currently used in healthcare environments where multidrug resistance is prominent. Because there is a constant potential for resistance to emerge, survey...

...S. Roveta; A. Marchese; E.A. Debbia Background: In this study (part of the global TEST program), the in vitro activity of tigecycline, a member of a new class of antimicrobial agents, the glycylcyclines, against clinical isolates collected in Italy was evaluated. Methods: A total of 200 clinical...